Fresenius Medical Care AG & Co. (NYSE:FMS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Fresenius has had a favorable run on the bourse over the last year. A solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts. On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

FMS has been the subject of several other research reports. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, January 2nd. UBS Group raised Fresenius Medical Care AG & Co. from a “sell” rating to a “neutral” rating in a research note on Thursday, January 4th. DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, December 18th. Morgan Stanley lowered Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. Finally, SunTrust Banks set a $62.00 price target on Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a research note on Thursday, December 21st. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $56.00.

Fresenius Medical Care AG & Co. (NYSE FMS) traded down $0.21 during trading on Tuesday, reaching $55.54. The company had a trading volume of 98,400 shares, compared to its average volume of 141,893. Fresenius Medical Care AG & Co. has a twelve month low of $40.02 and a twelve month high of $55.76. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. The stock has a market capitalization of $34,169.40, a PE ratio of 24.91, a price-to-earnings-growth ratio of 2.30 and a beta of 0.45.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its earnings results on Thursday, November 2nd. The company reported $0.59 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a return on equity of 11.51% and a net margin of 7.04%. The business had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.36 billion. equities research analysts predict that Fresenius Medical Care AG & Co. will post 2.38 EPS for the current year.

Hedge funds have recently modified their holdings of the business. UBS Asset Management Americas Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. by 3.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after acquiring an additional 81 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Fresenius Medical Care AG & Co. by 4.0% in the 2nd quarter. Advisor Group Inc. now owns 8,168 shares of the company’s stock valued at $393,000 after acquiring an additional 312 shares during the last quarter. Mariner Wealth Advisors LLC lifted its stake in shares of Fresenius Medical Care AG & Co. by 6.9% in the 2nd quarter. Mariner Wealth Advisors LLC now owns 6,882 shares of the company’s stock valued at $333,000 after acquiring an additional 445 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of Fresenius Medical Care AG & Co. by 11.6% in the 2nd quarter. MML Investors Services LLC now owns 7,208 shares of the company’s stock valued at $348,000 after acquiring an additional 748 shares during the last quarter. Finally, YorkBridge Wealth Partners LLC lifted its stake in shares of Fresenius Medical Care AG & Co. by 19.4% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock valued at $222,000 after acquiring an additional 749 shares during the last quarter. 3.03% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Fresenius Medical Care AG & Co. (FMS) Downgraded by Zacks Investment Research to Hold” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2018/01/23/fresenius-medical-care-ag-co-fms-downgraded-by-zacks-investment-research-to-hold.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.